| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -22,003 | -18,071 | - | - |
| Income tax expense | - | 283 | - | - |
| Net loss | -22,003 | -18,354 | -21,158 | -21,203 |
| Net unrealized gain (loss) on marketable debt securities | 74 | -54 | -121 | 453 |
| Other comprehensive gain (loss) | 74 | -54 | -121 | 453 |
| Comprehensive loss | -21,929 | -18,408 | -21,279 | -20,750 |
| Earnings per share, basic, total | -0.35 | -0.3 | -0.35 | -0.35 |
| Earnings per share, diluted, total | -0.35 | -0.3 | -0.35 | -0.35 |
| Weighted average number of shares outstanding, basic | 62,557,386 | 61,918,826 | 61,048,948 | 60,715,041 |
| Weighted average number of shares outstanding, diluted, total | 62,557,386 | 61,918,826 | 61,048,948 | 60,715,041 |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)